<!DOCTYPE html>
<html>
<head>
<style>
.rectangle1{
  width: 100%;
  height: 100px;
  background: #DADBDD;
  text-align: center;



}

body {
           text-align: center;
           /*background-image: url('img_girl.jpeg');*/
       }
.tableth{
  text-align:center;
  background-color:#FF6600;
  padding: 4px 30px 4px 8px;
  font-size:23px;
}
.tabletd{
  border: 1px solid #e3e3e3;
  padding:4px 8px;
  text-align:left;

  width:50%


}

</style>
</head>
<body>
  <div class= "rectangle1">
    <h1 class="center" style="color:black;" style="font-size:25px;">
      MRI Department
     </h1>
     <h2 class="center" style="color:black;" style="font-size:22px;">
       Pain point & solution  analysis
      </h2>
  </div>
  <table>
    <tr>
      <th class="tableth" style="color:white;" >Pain Points</th>
      <th class="tableth" style="color:white;">Solutions</th>
    </tr>


    <tr>
      <td class="tabletd" style= "background-color: #FED8B1; font-size:16pt;" rowspan="2"> By the time of diagnosis, the disease is often already in middle or later stages since PD diagnosis is mainly based on medical history and physical examination.
    </td>
    <td class="tabletd" style= "background-color: #FED8B1; font-size:12pt;" > <b> Hybrid PET MRI for early detection:  </b> Besides use of PET/ SPECT for PD diagnosis, hybrid PET-MRI can do the simultaneous detection of various elements of brain abnormalities for early diagnosis of PD patient’s molecular changes and dopaminergic system microstructural deterioration.

    </td>
    </tr>
    <tr>
    <td class="tabletd" style="background-color: #FED8B1; font-size:12pt;"> <b>CNN based spiral drawings analysis: </b>Convolutional neural networks that analyze images of spirals that are drawn by the patients can detect Parkinson's disease. The neural network completes the image processing, and the data gets compared to the dataset; which indicates if the patient has Parkinson's or not   </td>
    </tr>


    <tr>
      <td class="tabletd" style= "background-color: #FED8B1; font-size:16pt;"> There is no well-established in vivo marker of nigral degeneration in Parkinson's disease
    </td>
    <td class="tabletd" style= "background-color: #FED8B1; font-size:12pt;"> <b>Visualization of nigrosome-1: </b> Poor visualization of nigrosome-1 (a dopaminergic neuron-rich region in the substantial nigra) is observed in patients with PD as compared to non-PD patients. It has potential diagnostic properties as a neuroimaging biomarker in PD if assessed with at least 3T MRI technology.

     </td>
    </tr>

    <tr>
      <td class="tabletd" style= "background-color: #FED8B1;font-size:16pt;"> Pathologically folded α-synuclein accumulates in the brain of PD patients. A new test detects this protein also in neuronal extracellular vesicles contained in the patient’s blood. In future, this may help to distinguish between PD patients and healthy individuals.
    
    </td>
    <td class="tabletd" style= "background-color: #FED8B1; font-size:12pt;"> <b>7T MRI technology:  </b>  Patients are more likely to benefit from noradrenaline boosting therapy if they have damage to the locus coeruleus. The ultra-powerful 7T scanner may help identify such patients.
     </td>
    </tr>

    </table>

    </body>
    </html>
